Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04706533 · ClinicalTrials.gov registry record
Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19
A clinical trial of COVID-19 and Inflammation, sponsored by University of Michigan.
- Completed
- Registry status
- 3,402
- Enrollment target
- 1
- Study location
NCT04706533: Completed study of COVID-19 and Inflammation, sponsored by University of Michigan.
NCT04706533 is a study of COVID-19 and Inflammation that has completed, run by University of Michigan. The registered enrollment target is 3,402 participants, below the 38,454-participant average among 298 other COVID-19 trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04706533, a study of COVID-19 and Inflammation, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 3,402 participants
- Enrollment target
- 1
- Study location
Study Summary
To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with severe COVID-19 admitted at the University of Michigan. The purpose of M2C2 is to define the in-hospital course of these patients and understand the role of inflammation as a determinant of organ injury and outcomes in COVID-19.
Primary Outcome
The primary outcome is a composite endpoint, which is defined as the need for mechanical ventilation, the need for dialysis, or in-hospital death.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Biomarkers of inflammation
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,402 participants |
| Start Date | 2020-03-23 |
| Est. Completion | 2022-12-01 |
What the finished NCT04706533 record still lists
NCT04706533 is an observational study that tracks outcomes without assigning an intervention. Its 3,402 participants enrollment target places it among the larger protocols in the corpus, below the 38,454-participant average among 298 other COVID-19 trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Biomarkers of inflammation is the first listed.
NCT04706533 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04706533 about?
NCT04706533 is a clinical study titled "Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19". To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with severe COVID-19 admitted at the University of Michigan. The purpose of M2...
What is the current status of trial NCT04706533?
This trial is currently completed. The enrollment target is 3,402 participants. The study started on 2020-03-23. Estimated completion is 2022-12-01.
What conditions does trial NCT04706533 study?
This clinical trial studies the following conditions: COVID-19, Inflammation, Kidney Diseases, SARS-CoV Infection.
What interventions are being tested in trial NCT04706533?
The interventions under investigation include: Biomarkers of inflammation (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04706533?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04706533 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04706533's enrollment target sits among peer trials
3,402 36th of 298 higher than 263 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI